Want to see AU:MSB full AI Analyst Report?
MSB Stock Chart & Stats
AU$2.22
-AU$0.08(-3.60%)
At close: 4:00 PM EDT
AU$2.22
-AU$0.08(-3.60%)
Day’s Range― - ―
52-Week RangeAU$1.88 - AU$3.31
Previous CloseN/A
Volume2.85M
Average Volume (3M)4.33M
Market Cap
AU$2.66B
Enterprise ValueAU$3.52K
Total Cash (Recent Filing)AU$129.57M
Total Debt (Recent Filing)AU$135.14M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Sep 02, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding1,298,748,200
10 Day Avg. Volume4,518,407
30 Day Avg. Volume4,325,729
Financial Highlights & Ratios
PEG Ratio-27.18
Price to Book (P/B)2.09
Price to Sales (P/S)72.48
P/FCF Ratio-24.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.56Price Target Upside60.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$200.94M
Bulls Say, Bears Say
Bulls Say
Successful Ryoncil Commercial LaunchMaterial H1 revenues from a newly launched product demonstrate early commercial product-market fit and sales execution. Durable impact: a proven revenue engine reduces binary clinic-readout risk, creates channel relationships, and underpins reinvestment in pipeline and commercialization over the next 2–6 months.
Industry-leading Gross MarginsVery high gross margins indicate strong unit economics for the cell-therapy product, enabling revenue to more directly fund SG&A and R&D. This structural margin advantage supports long-term scalability if manufacturing scale-up and COGS control are maintained.
Broad Payer Coverage & Rapid AdoptionBroad reimbursement access and fast center onboarding materially lower adoption friction and support sustainable demand. Durable effect: established payer policies and J-code coverage make continued utilization and volume growth more likely across pediatric and expansion adult markets.
Bears Say
Revenue Concentration RiskNearly all current revenue derives from one recently launched product, leaving top-line stability exposed to utilization, reimbursement changes, or manufacturing disruptions. Over 2–6 months this amplifies earnings volatility until other programs or durable multi-product sales emerge.
Operating Cash Burn And Tranche TimingNegative operating cash flow and a time-limited optional credit tranche create a structural liquidity dependency on hitting revenue targets or drawing financing by June 2026. Failure to access funds or meet guidance could force operational trade-offs or dilutive financing.
Manufacturing/CMC And Regulatory Execution RiskComplex biologic manufacturing, potency assay validation and unresolved labeling discussions introduce durable execution risk for upcoming BLA filings. Delays or additional data requests can defer approvals, impair revenue scaling and raise incremental COGS or capex needs.
Mesoblast Limited News
MSB FAQ
What was Mesoblast Limited’s price range in the past 12 months?
Mesoblast Limited lowest share price was AU$1.88 and its highest was AU$3.31 in the past 12 months.
What is Mesoblast Limited’s market cap?
Mesoblast Limited’s market cap is AU$2.66B.
When is Mesoblast Limited’s upcoming earnings report date?
Mesoblast Limited’s upcoming earnings report date is Sep 02, 2026 which is in 28 days.
How were Mesoblast Limited’s earnings last quarter?
Mesoblast Limited released its earnings results on Feb 27, 2026. The company reported -AU$0.044 earnings per share for the quarter, missing the consensus estimate of -AU$0.01 by -AU$0.034.
Is Mesoblast Limited overvalued?
According to Wall Street analysts Mesoblast Limited’s price is currently Undervalued.
Does Mesoblast Limited pay dividends?
Mesoblast Limited does not currently pay dividends.
What is Mesoblast Limited’s EPS estimate?
Mesoblast Limited’s EPS estimate is >-0.01.
How many shares outstanding does Mesoblast Limited have?
Mesoblast Limited has 1,298,748,200 shares outstanding.
What happened to Mesoblast Limited’s price movement after its last earnings report?
Mesoblast Limited reported an EPS of -AU$0.044 in its last earnings report, missing expectations of -AU$0.01. Following the earnings report the stock price went down -7.589%.
Which hedge fund is a major shareholder of Mesoblast Limited?
Currently, no hedge funds are holding shares in AU:MSB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mesoblast Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$3.56 (60.36% Upside)
AU$3.56 (60.36% Upside)
Blogger Sentiment
Bullish
AU:MSB Sentiment 95%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.82%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.74%
Trailing 12-Months
Company Description
Mesoblast Limited
Mesoblast Limited (ASX: MSB) is a clinical-stage biotechnology company focused on developing allogeneic (off-the-shelf) cell therapies based on mesenchymal lineage cells (MLCs) for inflammatory diseases. The company’s programs have targeted conditions such as steroid-refractory acute graft-versus-host disease (aGVHD), chronic heart failure, and other immune-mediated disorders, with development historically spanning clinical trials, regulatory submissions, and (where applicable) preparation for commercialization through partners.
MSB Stock 12 Month Forecast
Average Price Target
AU$3.56
▲(60.36% Upside)
Technical Analysis
Cynata Therapeutics Limited
―
Living Cell Technologies
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―